Skip to Content
Merck
CN

Key Documents

View All Documentation

78544

Glucose tetrasaccharide

≥99.0% (TLC)

Synonym(s):

Glcα1-6Glcα1-4Glcα1-4Glc

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C24H42O21
CAS Number:
35175-16-7
Molecular Weight:
666.58
NACRES:
NA.28
PubChem Substance ID:
329768157
UNSPSC Code:
12352201
MDL number:
MFCD09840666
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥99.0% (TLC)

form

powder

color

white

suitability

corresponds for LC-MS

storage temp.

room temp

SMILES string

OC[C@H]1O[C@H](OC[C@H]2O[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3CO)O[C@H]4[C@H](O)[C@@H](O)C(O)O[C@@H]4CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O

InChI

1S/C24H42O21/c25-1-5-9(28)11(30)16(35)22(41-5)39-4-8-10(29)12(31)17(36)23(43-8)45-20-7(3-27)42-24(18(37)14(20)33)44-19-6(2-26)40-21(38)15(34)13(19)32/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11+,12+,13-,14-,15-,16-,17-,18-,19-,20-,21?,22+,23-,24-/m1/s1

InChI key

FPBCRLIOSBQLHS-QVTSYAGHSA-N

Application

Glucose tetrasaccharide (Glc4) is used as a reference in analysis of urinary glucose tetrasacchaide, a biomarker for Pompe disease and other glycogen storage diseases.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Other Notes

To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

涉药品监管产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCH1188
BCCF9175
BCCB9931
BCCB2907
BCBX1038

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yoav H Messinger et al.
Genetics in medicine : official journal of the American College of Medical Genetics, 14(1), 135-142 (2012-01-13)
Infantile Pompe disease resulting from a deficiency of lysosomal acid α-glucosidase (GAA) requires enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA). Cross-reactive immunologic material negative (CRIM-negative) Pompe patients develop high-titer antibody to the rhGAA and do poorly. We describe
Victoria Manwaring et al.
Journal of inherited metabolic disease, 35(2), 311-316 (2011-06-21)
A high performance liquid chromatography method, adapted from an established urinary sugars method, has been developed for the analysis of a tetraglucose oligomer (Glc(4)) in urine. Pompe disease results from defects in the activity of lysosomal acid α-glucosidase (GAA) with
Zoheb B Kazi et al.
Genetics in medicine : official journal of the American College of Medical Genetics, 21(4), 887-895 (2018-09-15)
To investigate immune tolerance induction with transient low-dose methotrexate (TLD-MTX) initiated with recombinant human acid α-glucosidase (rhGAA), in treatment-naïve cross-reactive immunologic material (CRIM)-positive infantile-onset Pompe disease (IOPD) patients. Newly diagnosed IOPD patients received subcutaneous or oral 0.4 mg/kg TLD-MTX for 3
View All Related Papers

Global Trade Item Number

SKUGTIN
78544-1MG04061826054536